ENO1 and myelodysplastic syndrome: Overall, anti-ENO1 levels were significantly different between the cohorts (p = 0.0024), with AML patients having significantly lower circulating levels of anti-ENO1 autoantibodies compared to controls (median, range = 1.63, 0.00–36.90 vs. 11.24 (0–40.17) ng/mL, p = 0.0019, Figure 3A), resulting in a positive test for trend (controls > MDS > AML, p = 0.0032).